Cargando…
Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer Health
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213617/ https://www.ncbi.nlm.nih.gov/pubmed/32149772 http://dx.doi.org/10.1097/CM9.0000000000000790 |
| _version_ | 1783531826991595520 |
|---|---|
| author | Zeng, Yan-Ming Xu, Xiao-Lei He, Xiao-Qing Tang, Sheng-Quan Li, Yao Huang, Yin-Qiu Harypursat, Vijay Chen, Yao-Kai |
| author_facet | Zeng, Yan-Ming Xu, Xiao-Lei He, Xiao-Qing Tang, Sheng-Quan Li, Yao Huang, Yin-Qiu Harypursat, Vijay Chen, Yao-Kai |
| author_sort | Zeng, Yan-Ming |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7213617 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Wolters Kluwer Health |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-72136172020-06-15 Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol Zeng, Yan-Ming Xu, Xiao-Lei He, Xiao-Qing Tang, Sheng-Quan Li, Yao Huang, Yin-Qiu Harypursat, Vijay Chen, Yao-Kai Chin Med J (Engl) Correspondence Wolters Kluwer Health 2020-05-05 2020-05-05 /pmc/articles/PMC7213617/ /pubmed/32149772 http://dx.doi.org/10.1097/CM9.0000000000000790 Text en Copyright © 2020 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 |
| spellingShingle | Correspondence Zeng, Yan-Ming Xu, Xiao-Lei He, Xiao-Qing Tang, Sheng-Quan Li, Yao Huang, Yin-Qiu Harypursat, Vijay Chen, Yao-Kai Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol |
| title | Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol |
| title_full | Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol |
| title_fullStr | Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol |
| title_full_unstemmed | Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol |
| title_short | Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol |
| title_sort | comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213617/ https://www.ncbi.nlm.nih.gov/pubmed/32149772 http://dx.doi.org/10.1097/CM9.0000000000000790 |
| work_keys_str_mv | AT zengyanming comparativeeffectivenessandsafetyofribavirinplusinterferonalphalopinavirritonavirplusinterferonalphaandribavirinpluslopinavirritonavirplusinterferonalphainpatientswithmildtomoderatenovelcoronavirusdisease2019studyprotocol AT xuxiaolei comparativeeffectivenessandsafetyofribavirinplusinterferonalphalopinavirritonavirplusinterferonalphaandribavirinpluslopinavirritonavirplusinterferonalphainpatientswithmildtomoderatenovelcoronavirusdisease2019studyprotocol AT hexiaoqing comparativeeffectivenessandsafetyofribavirinplusinterferonalphalopinavirritonavirplusinterferonalphaandribavirinpluslopinavirritonavirplusinterferonalphainpatientswithmildtomoderatenovelcoronavirusdisease2019studyprotocol AT tangshengquan comparativeeffectivenessandsafetyofribavirinplusinterferonalphalopinavirritonavirplusinterferonalphaandribavirinpluslopinavirritonavirplusinterferonalphainpatientswithmildtomoderatenovelcoronavirusdisease2019studyprotocol AT liyao comparativeeffectivenessandsafetyofribavirinplusinterferonalphalopinavirritonavirplusinterferonalphaandribavirinpluslopinavirritonavirplusinterferonalphainpatientswithmildtomoderatenovelcoronavirusdisease2019studyprotocol AT huangyinqiu comparativeeffectivenessandsafetyofribavirinplusinterferonalphalopinavirritonavirplusinterferonalphaandribavirinpluslopinavirritonavirplusinterferonalphainpatientswithmildtomoderatenovelcoronavirusdisease2019studyprotocol AT harypursatvijay comparativeeffectivenessandsafetyofribavirinplusinterferonalphalopinavirritonavirplusinterferonalphaandribavirinpluslopinavirritonavirplusinterferonalphainpatientswithmildtomoderatenovelcoronavirusdisease2019studyprotocol AT chenyaokai comparativeeffectivenessandsafetyofribavirinplusinterferonalphalopinavirritonavirplusinterferonalphaandribavirinpluslopinavirritonavirplusinterferonalphainpatientswithmildtomoderatenovelcoronavirusdisease2019studyprotocol |